Novo Nordisk to slash US list prices of Ozempic and Wegovy, WSJ reports

Group 1 - Danish drugmaker Novo Nordisk plans to reduce U.S. list prices of its diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% starting next year [1] - The decision comes amid increasing scrutiny and pressure on drug pricing in the U.S. healthcare market [1] - The price cut is expected to significantly impact the accessibility of these medications for patients [1] Group 2 - Ozempic and Wegovy are considered blockbuster drugs, indicating their substantial sales and market presence [1] - The move may reflect a broader trend in the pharmaceutical industry towards more competitive pricing strategies [1] - Novo Nordisk's pricing strategy could influence other companies in the healthcare sector to reconsider their pricing models [1]